中国医院协会临床微生物实验室专业委员会;
Sub-committee of Clinical Microbiology Laboratory,China Hospital Association;

摘要(Abstract)：

新型冠状病毒肺炎疫情持续时间长、流行范围广，给全球公共卫生带来了巨大负担。作为感染早期诊断和疫情防控的主要检测手段之一，新型冠状病毒抗原快速检测已在国内逐步开展临床应用。就目前医务人员和社会公众所关注的新型冠状病毒抗原检测相关问题，中国医院协会临床微生物实验室专业委员会组织医学检验、临床医学、感染控制、公共卫生及体外诊断产品研发等多领域专家，依据国内外最新研究进展和应用实践，共同制定了《新型冠状病毒抗原快速检测专家共识(2022)》。本共识介绍了目前新型冠状病毒抗原快速检测方法的技术原理、性能特点、结果解读及处置建议，并就不同场景下新型冠状病毒抗原快速检测应用策略和注意事项进行了解析，以期为临床诊疗和疫情防控中正确理解和应用这一检测技术提供参考建议。
The epidemic of the highly contagious, long lasting and widely popular coronavirus disease 2019(COVID-19) has imposed a huge burden to the global public health. As one of the key methods for early diagnosis of COVID-19 infection, rapid acute respiratory syndrome coronavirus 2(SARS-CoV-2) antigen testing has been gradually applied in China. To address concerns raised by both health care workers and the public, based on the latest research and clinical practices, the Sub-committee of Clinical Microbiology Laboratory, Chinese Hospital Association proposed Expert Consensus on Rapid SARS-CoV-2 Antigen Testing(2022). The consensus panel is composed of experts from multiple disciplines, including laboratory medicine, clinical medicine, infection control, public health, research and development of in vitro diagnostic products. The consensus describes its principle, technological characteristics, results interpretation and disposal recommendations, and analyzes the strategies and matters needing attention in different application scenarios. We expect the consensus to help correct understanding and application of rapid SARS-CoV-2 antigen testing inthe diagnosis, treatment, prevention, and control of COVID-19.

关键词(KeyWords)： 新型冠状病毒;新型冠状病毒肺炎;抗原快速检测;专家共识
severe acute respiratory syndrome coronavirus 2;coronavirus disease 2019;rapid antigen test;expert consensus

Abstract:

Keywords:

基金项目(Foundation): 中国医学科学院医学与健康科技创新工程(2021-I2M-1-038)~~

作者(Authors): 中国医院协会临床微生物实验室专业委员会;
Sub-committee of Clinical Microbiology Laboratory,China Hospital Association;

参考文献(References)：

• [1] 国家卫生健康委员会办公厅，国家中医药管理局办公室.关于印发新型冠状病毒肺炎诊疗方案(试行第九版)的通知(国卫办医函[2022]71号)[EB/OL].(2022-03-14)[2022-04-10].http://www.gov.cn/zhengce/zheng ceku/2022- 03/15/content_5679257.htm.
• [2] 国务院应对新型冠状病毒肺炎疫情联防联控机制综合组.关于印发新冠病毒抗原检测应用方案(试行)的通知(联防联控机制综发[2022]21号)[EB/OL].(2022- 03- 11) [2022- 04- 10].http://www.nhc.gov.cn/yzygj/s7659/202203/d4d7fb72088447f7a4f9cd10966a67eb.shtml.
• [3] 医政医管局.新冠病毒抗原检测应用方案(试行)政策解读[EB/OL].(2022- 03- 11) [2022- 04- 10].http://www.nhc.gov.cn/yzygj/s7659/202203/4573dfb9cca244509 c29b964ba287889.shtml.
• [4] 国家药品监督管理局.医疗器械数据查询[EB/OL].(2022- 04- 07) [2022- 04- 10].https://www.nmpa.gov.cn/datasearch/ search- result.html.
• [5] World Health Organization.WHO Emergency Use Listing for in vitro diagnostics (IVDs) detecting SARS-CoV- 2[EB/OL].(2022- 02- 23) [2022- 04- 10].https://extranet.who.int/pqweb/sites/default/files/documents/220223_EUL_SARS-CoV- 2_product_list.pdf.
• [6] U.S.Food & Drug Administration.In Vitro Diagnostics EUAs-Antigen Diagnostic Tests for SARS-CoV- 2[EB/OL].(2022- 04- 07) [2022- 04- 10].https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-anti-gen-diagnostic-tests-sars-cov- 2.
• [7] European Commission Directorate-General for Health and Food Safety.EU health preparedness:A common list of COVID- 19 rapid antigen tests;A common standardised set of data to be included in COVID- 19 test result certificates;and A common list of COVID- 19 laboratory based antigenic assays[EB/OL].(2022- 03- 30) [2022- 04- 10].https://ec.europa.eu/health/system/files/2022- 03/covid- 19_rat_common-list_en_1.pdf.
• [8] 范曼如，申泉，王丹琦，等.临床实践指南制订方法：形成推荐意见的共识方法学[J].中国循证心血管医学杂志，2019,11:647- 653.
• [9] 北京协和医院罕见病多学科协作组，中国罕见病联盟.多准则决策分析应用于罕见病药品临床综合评价的专家共识(2022)[J].协和医学杂志，2022,13:126- 145.
• [10] Kandimalla R,John A,Abburi C,et al.Current Status of Multiple Drug Molecules,and Vaccines:An Update in SARS-CoV- 2 Therapeutics[J].Mol Neurobiol,2020,57:4106- 4116.
• [11] Zandi M,Soltani S.Hemagglutinin-esterase cannot be considered as a candidate for designing drug against COVID- 19[J].Mol Divers,2021,25:1999- 2000.
• [12] Scheiblauer H,Filomena A,Nitsche A,et al.Comparative sensitivity evaluation for 122 CE-marked rapid diagnostic tests for SARS-CoV- 2 antigen,Germany,September 2020 to April 2021[J].Euro Surveill,2021,26:2100441.
• [13] Peng Y,Du N,Lei Y,et al.Structures of the SARS-CoV- 2 nucleocapsid and their perspectives for drug design[J].EMBO J,2020,39:e105938.
• [14] 世界卫生组织.抗原检测用于诊断SARS-CoV- 2感染：临时指导文件[EB/OL].(2021- 10- 06) [2022- 04- 10].https://apps.who.int/iris/bitstream/handle/10665/345948/ WHO- 2019-nCoV-Antigen-Detection- 2021.1-chi.pdf.
• [15] 刘巨钊，杨玉萍，徐建波，等.新冠病毒S蛋白RBD突变侵染性增强潜在分子作用机制[J/OL].生物学杂志，2022:1- 8.[2022- 04- 09].http://kns.cnki.net/kcms/detail/34.1081.q.20220321.1514.002.html.
• [16] 徐本锦，范蕾，杜淼，等.新冠病毒核衣壳蛋白结构与功能的生物信息学分析及原核表达[J/OL].中国免疫学杂志，2021:1- 25.http://kns.cnki.net/kcms/detail/22.1126.R.20210924.0101.002.html.
• [17] Bates TA,Weinstein JB,Farley S,et al.Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV- 2[J].Cell Rep,2021,34:108737.
• [18] Corman VM,Haage VC,Bleicker T,et al.Comparison of seven commercial SARS-CoV- 2 rapid point-of-care antigen tests:a single-centre laboratory evaluation study[J].Lancet Microbe,2021,2:e311-e319.
• [19] Seo G,Lee G,Kim MJ,et al.Rapid Detection of COVID- 19 Causative Virus (SARS-CoV- 2) in Human Nasopharyn-geal Swab Specimens Using Field-Effect Transistor-Based Biosensor[J].ACS Nano,2020,14:5135- 5142.
• [20] Mahari S,Roberts A,Shahdeo D,et al.eCovSens-Ultrasensitive Novel In-House Built Printed Circuit Board Based Electrochemical Device for Rapid Detection of nCovid- 19 antigen,a spike protein domain 1 of SARS-CoV- 2[J].bioRxiv,2020.doi:10.1101/2020.04.24.059204.
• [21] Dinnes J,Deeks JJ,Berhane S,et al.Rapid,point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV- 2 infection[J].Cochrane Database Syst Rev,2021,3:CD013705.
• [22] Bruzzone B,De Pace V,Caligiuri P,et al.Comparative diagnostic performance of rapid antigen detection tests for COVID- 19 in a hospital setting[J].Int J Infect Dis,2021,107:215- 218.
• [23] Chaimayo C,Kaewnaphan B,Tanlieng N,et al.Rapid SARS-CoV- 2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID- 19 in Thailand[J].Virol J,2020,17:177.
• [24] Brümmer LE,Katzenschlager S,Gaeddert M,et al.Accur-acy of novel antigen rapid diagnostics for SARS-CoV- 2:A living systematic review and meta-analysis[J].PLoS Med,2021,18:e1003735.
• [25] Smith RL,Gibson LL,Martinez PP,et al.Longitudinal Assessment of Diagnostic Test Performance Over the Course of Acute SARS-CoV- 2 Infection[J].J Infect Dis,2021,224:976- 982.
• [26] Khalid MF,Selvam K,Jeffry A,et al.Performance of Rapid Antigen Tests for COVID- 19 Diagnosis:A Systematic Review and Meta-Analysis[J].Diagnostics (Basel),2022,12:110.
• [27] Deng Q,Ye G,Pan Y,et al.High Performance of SARS-Cov- 2N Protein Antigen Chemiluminescence Immunoassay as Frontline Testing for Acute Phase COVID- 19 Diagnosis:A Retrospective Cohort Study[J].Front Med (Lausanne),2021,8:676560.
• [28] Yokoyama R,Kurano M,Nakano Y,et al.Association of the Serum Levels of the Nucleocapsid Antigen of SARS-CoV- 2 With the Diagnosis,Disease Severity,and Antibody Titers in Patients With COVID- 19:A Retrospective Cross-Sectional Study[J].Front Microbiol,2021,12:791489.
• [29] European Centre for Disease Prevention and Control.Options for the use of rapid antigen tests for COVID- 19 in the EU/EEA-first update[EB/OL].(2021- 10- 26)[2022- 04- 09].https://www.ecdc.europa.eu/en/publications-data/options-use-rapid-antigen-tests-covid- 19-eueea-first-update.
• [30] Jungnick S,Hobmaier B,Mautner L,et al.Detection of the new SARS-CoV- 2 variants of concern B.1.1.7 and B.1.351 in five SARS-CoV- 2 rapid antigen tests (RATs),Germany,March 2021[J].Euro Surveill,2021,26:2100413.
• [31] Pulliam J,van Schalkwyk C,Govender N,et al.Increased risk of SARS-CoV- 2 reinfection associated with emergence of Omicron in South Africa[J].Science,2022,376:eabn4947.
• [32] Saxena SK,Kumar S,Ansari S,et al.Characterization of the novel SARS-CoV- 2 Omicron (B.1.1.529) variant of concern and its global perspective[J].J Med Virol,2022,94:1738- 1744.
• [33] Soni A,Herbert C,Filippaios A,et al.Comparison of Rapid Antigen Tests' Performance between Delta (B.1.61.7;AY.X) and Omicron (B.1.1.529;BA1) Variants of SARS-CoV- 2:Secondary Analysis from a Serial Home Self-Testing Study[J].medRxiv,2022.doi:10.1101/2022.02.27.22271090.
• [34] Bekliz M,Perez-Rodriguez F,Puhach O,et al.Sensitivity of SARS-CoV- 2 antigen-detecting rapid tests for Omicron variant[J].medRxiv,2021.doi:https://www.medrxiv.org/content/10.1101/2021.12.18.21268018.
• [35] Deerain J,Druce J,Tran T,et al.Assessment of the Analytical Sensitivity of 10 Lateral Flow Devices against the SARS-CoV- 2 Omicron Variant[J].J Clin Microbiol,2022,60:e247921.
• [36] Bullard J,Dust K,Funk D,et al.Predicting Infectious Severe Acute Respiratory Syndrome Coronavirus 2 From Diagnostic Samples[J].Clin Infect Dis,2020,71:2663- 2666.
• [37] U.S.FOOD & DRUG ADMINISTRATION.Potential for False Positive Results with Antigen Tests for Rapid Detection of SARS-CoV- 2-Letter to Clinical Laboratory Staff and Health Care Providers[EB/OL].(2020- 11- 03)[2022- 04-10].https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-positive-results-antigen-tests-rapid-detection-sars-cov- 2-letter-clinical-laboratory.
• [38] Mouliou DS,Gourgoulianis KI.False-positive and false-negative COVID- 19 cases:respiratory prevention and management strategies,vaccination,and further perspectives[J].Expert Rev Respir Med,2021,15(8):993- 1002.
• [39] Larremore DB,Wilder B,Lester E,et al.Test sensitivity is secondary to frequency and turnaround time for COVID- 19 screening[J].Sci Adv,2021,7:eabd5393.
• [40] Mina MJ,Parker R,Larremore DB.Rethinking Covid- 19 Test Sensitivity-A Strategy for Containment[J].N Engl J Med,2020,38:e120.
• [41] 国务院应对新型冠状病毒肺炎疫情联防联控机制综合组.基层医疗卫生机构新冠病毒抗原检测基本要求及流程[EB/OL].(2022- 03- 10)[2022- 04-10].http://www.nhc.gov.cn/yzygj/s7659/202203/d4d7fb72088447f7a4f9cd 10966a67eb/files/b62d9eeeca8242b3a22e78a25ef 9fd92.pdf.
• [42] 中国合格评定国家认可委员会.2019临床免疫学定性检验程序性能验证指南：CNAS-GL038[S].2019.
• [43] 国务院应对新型冠状病毒肺炎疫情联防联控机制综合组.新冠病毒抗原自测基本要求及流程[EB/OL].(2022- 03- 10) [2022- 04- 10].http://www.nhc.gov.cn/yzygj/s7659/202203/d4d7fb72088447f7a4f9cd10966a67eb/files/8db5dd22ccb84b6296bc4257ba7db9c0.pdf.
• [44] Stohr J,Zwart VF,Goderski G,et al.Self-testing for the detection of SARS-CoV- 2 infection with rapid antigen tests for people with suspected COVID- 19 in the community[J].Clin Microbiol Infect,2021,S1198- 743X(21)00434- 1.doi:10.1016/j.cmi.2021.07.039.
• [45] Maya S,Kahn JG.Cost-effectiveness of antigen testing for ending COVID- 19 isolation[J].medRxiv,2022,2022.03.21.22272687.doi:10.1101/2022.03.21.22272687.
• [46] 交通运输部，外交部，海关总署.关于做好国际航行船舶船员新冠肺炎疫情远端防控的公告(交通运输部公告2022年第14号)[EB/OL].(2022- 01- 28) [2022- 04- 10].http://www.gov.cn/zhengce/zhengceku/2022- 02/13/content_5673345.htm.
• [47] 天津市卫生健康委员会.市卫生健康委转发市防控指挥部关于印发天津市新冠病毒抗原检测应用阶段性实施方案(试行)的通知(津卫医政[2022]151号)[EB/OL].(2022- 03- 29) [2022- 04- 10].http://wsjk.tj.gov.cn/ZWGK3158/ZCFG6243_1/GZWJ625/202203/t20220329_5842885.html.